📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
225 analysed today
FollowTelegram
225
Today
149,626
All-time analysed
42,906
Positive
6,661
Negative
91,382
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
147 announcements match the current filters (relevance ≥ 5).
Windlas Biotech Q3 Revenue Up 20% to INR 233 Cr; Plant 6 Completion Set for FY26
Windlas Biotech reported a strong Q3 FY26 with revenue growing 20% YoY to INR 233 crores, marking its 12th consecutive quarter of record revenue. The CDMO vertical led the performance with 23% growth, while the Exports segment surged 36% due to increased penetration in semi-regulated markets. Management confirmed that Plant 6 is on track for mechanical completion by the end of FY26, which will bring the total revenue capacity to approximately INR 1,100 crores. For the first 9 months of FY26, the company achieved an EPS of INR 24.02, representing a 12% YoY increase.
Key Highlights
Q3 FY26 revenue grew 20% YoY to INR 233 Cr, while 9M FY26 revenue rose 19% to INR 666 Cr.
9M FY26 EBITDA (excluding ESOP expenses) stood at INR 89 Cr with a margin of 13.3%.
Exports vertical grew 36% in Q3 FY26, significantly outperforming domestic volume growth trends.
Plant 6 mechanical completion expected by end of FY26 with an estimated capex of INR 50-60 Cr.
Total revenue capacity target set at INR 1,000 Cr for oral solids and INR 100 Cr for injectables.
👀 What to Watch
Investors should focus on the successful commissioning and utilization of Plant 6 and the injectable facility as primary growth catalysts. The company's consistent 12-quarter revenue growth streak and expansion in high-margin exports make it a strong candidate for long-term portfolios in the CDMO space.
Windlas Biotech Faces Suspension of Codeine Syrup Production; ₹55.21 Cr Revenue Impact
Windlas Biotech has received a Show Cause Notice from the Food Safety & Drug Administration (Uttarakhand), resulting in the temporary suspension of Codeine-containing cough syrup manufacturing. This specific product line contributed ₹55.21 crore to the company's total revenue in the current financial year as of February 9, 2026. While the suspension is limited to this product category, the company is preparing a detailed response to address the regulatory concerns and resume operations. Investors should monitor the duration of this suspension as it affects a material revenue stream.
Key Highlights
Temporary suspension of Codeine-containing cough syrup manufacturing by Uttarakhand authorities.
Affected product line contributed ₹55.21 crore to revenue in the current FY up to Feb 9, 2026.
Suspension is limited to Codeine-based products; other manufacturing operations remain unaffected.
Company is in the process of filing a detailed response to the Show Cause Notice within stipulated timelines.
👀 What to Watch
Investors should monitor the duration of the suspension as the affected revenue is significant. Watch for the company's formal response and any further regulatory actions or clearances from the Food Safety & Drug Administration.
Neuland Labs Q3FY26 Results: PAT Drops 60.2% YoY to Rs 40.4 Cr as Margins Contract
Neuland Laboratories reported a challenging Q3FY26 with a significant 60.2% YoY decline in Profit After Tax (PAT) to Rs 40.4 crore. While Total Income grew 11.4% YoY to Rs 447.8 crore, it fell 13.2% on a sequential basis. The company faced severe margin pressure, with EBITDA margins contracting to 19.0% from 30.4% in the previous quarter, driven by an unfavorable product mix and higher operating expenses. Management remains focused on long-term investments despite the current subdued profitability.
Key Highlights
Total Income for Q3FY26 reached Rs 447.8 crore, up 11.4% YoY but down 13.2% QoQ.
EBITDA fell 5.9% YoY and 45.8% QoQ to Rs 85.0 crore.
EBITDA margins contracted sharply to 19.0%, down from 22.5% YoY and 30.4% QoQ.
Profit After Tax (PAT) plummeted 60.2% YoY to Rs 40.4 crore compared to Rs 101.4 crore in Q3FY25.
Management cited product mix shifts and increased operating expenses as primary reasons for subdued margins.
👀 What to Watch
Investors should exercise caution due to the sharp sequential decline in margins and profitability. It is essential to monitor management's guidance on the recovery of the product mix and the impact of ongoing investments on future earnings.
Neuland Labs Q3FY26: Revenue Grows 11% YoY, but PAT Declines 60% on Margin Pressure
Neuland Laboratories reported a mixed Q3FY26 with total income rising 11.4% YoY to ₹447.8 crore, supported by growth in the CMS and Prime segments. However, EBITDA margins contracted significantly by 350 bps to 19.0% due to an unfavorable product mix and higher operating expenses. Consequently, PAT for the quarter fell 60% YoY to ₹31.5 crore. Despite the bottom-line pressure, the company remains net debt-free with a cash surplus of ₹202.6 crore and continues to invest in R&D expansion.
Key Highlights
Total Income for Q3FY26 stood at ₹447.8 crore, up 11.4% YoY, while 9MFY26 income reached ₹1,264.4 crore.
EBITDA margin compressed to 19.0% in Q3FY26 from 22.5% in the previous year's quarter.
PAT for Q3FY26 dropped 60% YoY to ₹31.5 crore, with 9MFY26 PAT down 35% at ₹150.6 crore.
CMS segment remains robust with 98 active projects, including 19 commercial molecules and 10 in Phase-3.
Capital expenditure for 9MFY26 reached ₹254 crore, including plans for a new 140k sq. ft. R&D facility at Genome Valley.
👀 What to Watch
Investors should be cautious regarding the sharp margin contraction and PAT decline, which may lead to short-term stock price volatility. Focus on the management's ability to improve the product mix and the long-term growth potential of the expanding CMS project pipeline.
Neuland Labs Q3 FY26 PAT Drops 60% YoY to ₹40.4 Cr; EBITDA Margins Contract to 19%
Neuland Laboratories reported a mixed Q3 FY26 with total income growing 11.4% YoY to ₹447.8 crore, but profitability faced significant pressure. EBITDA fell 5.9% YoY to ₹85 crore, with margins contracting sharply to 19.0% from 22.5% a year ago due to an unfavorable product mix and higher operating expenses. Net profit saw a steep decline of 60.2% YoY to ₹40.4 crore, though the previous year's base was higher due to exceptional items. Management remains optimistic about long-term growth driven by the NCE drug substance segment and niche capabilities despite the short-term margin volatility.
Key Highlights
Total Income grew 11.4% YoY to ₹447.8 crore but declined 13.2% on a sequential (QoQ) basis.
EBITDA margins contracted by 350 bps YoY and 1,140 bps QoQ to 19.0%.
Profit After Tax (PAT) plummeted 60.2% YoY to ₹40.4 crore from ₹101.4 crore in the previous year.
Management cited unfavorable product mix and increased operating expenses as primary reasons for margin compression.
9MFY26 Total Income reached ₹1,264.5 crore with cumulative EBITDA at ₹284 crore.
👀 What to Watch
Investors should exercise caution due to the significant sequential margin compression and monitor the management's commentary on the sustainability of the current product mix. The stock may face short-term pressure until there is clarity on the recovery of EBITDA margins back toward the 25-30% range seen in previous quarters.
Neuland Labs Q3 PAT Drops 60% YoY to ₹40.57 Cr; Revenue Up 10.5% YoY
Neuland Laboratories reported a consolidated revenue of ₹439.71 crore for Q3 FY26, a 10.5% increase compared to ₹398.03 crore in the same quarter last year. However, Profit After Tax (PAT) saw a sharp decline of 60% YoY to ₹40.57 crore, down from ₹101.59 crore, partly due to a high base effect from an exceptional gain in the previous year. On a sequential basis, revenue fell 14.5% and PAT dropped 58% from Q2 FY26. Rising finance costs and manufacturing expenses further pressured margins during the quarter.
Key Highlights
Consolidated Revenue from Operations grew 10.5% YoY to ₹439.71 crore but declined 14.5% QoQ.
Net Profit (PAT) plummeted 60% YoY to ₹40.57 crore, impacted by higher operational costs and a lack of exceptional gains seen in the prior year.
Finance costs spiked to ₹6.79 crore compared to ₹2.22 crore in Q3 FY25, reflecting higher interest or debt obligations.
9M FY26 PAT stands at ₹151.33 crore, a 34.8% decrease from ₹232.30 crore in 9M FY25.
Geographically, USA and North America revenue grew to ₹191.80 crore, while India revenue saw a sharp decline to ₹91.59 crore from ₹172.07 crore in the previous quarter.
👀 What to Watch
Investors should exercise caution as the company faces significant margin pressure and a sharp sequential slowdown in revenue. Monitor management's commentary regarding the spike in finance costs and the volatility in the India segment revenue.
Windlas Biotech Re-appoints Founder and Two Independent Directors for 5-Year Terms
Windlas Biotech has approved the re-appointment of its founder, Mr. Ashok Kumar Windlass, as Whole-time Director for a five-year term starting May 2026. The board also re-appointed Chairman Mr. Vivek Dhariwal and Mr. Gaurav Gulati as Independent Directors for their second five-year terms. These moves ensure leadership continuity and maintain a board with deep expertise in pharmaceutical manufacturing and business strategy. The re-appointments are subject to shareholder approval and will extend the current leadership's tenure until 2031.
Key Highlights
Mr. Ashok Kumar Windlass re-appointed as Whole-time Director for a 5-year term from May 3, 2026, to May 2, 2031.
Chairman Vivek Dhariwal re-appointed as Independent Director for a second 5-year term starting May 6, 2026.
Gaurav Gulati re-appointed as Independent Director for a second 5-year term starting May 6, 2026.
The leadership team brings combined experience from major firms like Pfizer, Baxter, and Oyo Hotels.
👀 What to Watch
Investors should view this as a sign of management stability and continuity, which is beneficial for long-term strategic execution. No immediate action is required as the existing leadership remains in place.
Windlas Biotech Q3FY26: Revenue up 20% to Rs 233 Cr; 12th Consecutive Record Revenue Quarter
Windlas Biotech reported a strong 20% YoY revenue growth in Q3FY26, reaching Rs 233.1 crore, marking its 12th consecutive quarter of record revenue. While reported PAT for the quarter saw a marginal decline of 4% to Rs 14.9 crore due to non-cash ESOP expenses, adjusted PAT grew significantly. The core CDMO vertical, contributing over 70% of revenue, grew by 23% YoY, while the export segment surged by 36%. For the 9-month period, the company maintained healthy momentum with a 19% revenue increase and a 13% rise in reported PAT.
Key Highlights
Revenue from operations grew 20% YoY to Rs 233.1 crore in Q3FY26, driven by the CDMO segment.
Adjusted EBITDA (excluding ESOP expenses) for 9MFY26 rose 26% YoY to Rs 89 crore with a 13.3% margin.
CDMO revenue increased 23% YoY in Q3FY26, contributing 71.6% to the total revenue mix.
Export vertical showed significant traction with 36% YoY growth in Q3FY26, reaching Rs 13.2 crore.
Plant-6 is on track for mechanical completion by the end of FY26, signaling future capacity expansion.
👀 What to Watch
Investors should focus on the strong 20% top-line growth and the robust performance of the CDMO segment, looking past the reported PAT dip caused by non-cash ESOP expenses. The consistent revenue records and upcoming capacity at Plant-6 suggest a positive long-term growth trajectory for the company.
Windlas Biotech Q3FY26 Revenue up 20% to ₹233 Cr; Adjusted PAT Surges 38% YoY
Windlas Biotech reported its 12th consecutive quarter of record revenue, reaching ₹233 crore in Q3FY26, a 20% YoY increase. While reported PAT for Q3 fell 4% to ₹15 crore due to significant non-cash ESOP charges, the adjusted PAT (excluding ESOPs) surged 38% to ₹22 crore. The core CDMO vertical, contributing 73% of revenue, grew 23% in Q3, while the Exports segment jumped 36%. The company remains net debt-free with ₹213 crore in liquidity and expects to complete its Plant-6 expansion by the end of FY26.
Key Highlights
9MFY26 Revenue grew 19% YoY to ₹666 Cr, driven by strong performance across CDMO and Export verticals.
Adjusted EBITDA (excluding non-cash ESOP expenses) for 9MFY26 rose 26% YoY to ₹89 Cr with a 13.3% margin.
CDMO vertical revenue grew 23% YoY in Q3FY26 to ₹167 Cr, with 67% of the portfolio focused on complex generics.
Exports segment showed robust momentum with 36% YoY growth in Q3FY26, increasing penetration in RoW markets.
Maintains a strong financial position with ₹213 Cr liquidity and remains net debt-free.
👀 What to Watch
Investors should focus on the adjusted (Ex-ESOP) profit figures to assess operational performance, as non-cash accounting charges are temporarily masking strong bottom-line growth. The consistent revenue trajectory and shift toward complex generics and exports make this a positive long-term growth story.
Windlas Biotech Q3 Revenue Grows 19.5% YoY to ₹233 Cr; PAT Marginally Lower at ₹15 Cr
Windlas Biotech reported a 19.5% YoY increase in revenue for Q3 FY26, reaching ₹2,331.02 million. Despite the top-line growth, net profit declined slightly to ₹150.02 million from ₹155.76 million in the same quarter last year, impacted by a 30% rise in employee benefit expenses. For the nine-month period ending December 2025, the company maintained a positive trajectory with a 12.9% increase in net profit. The board also approved the dissolution of its non-operative US subsidiary to simplify the corporate structure.
Key Highlights
Q3 FY26 Revenue from Operations increased 19.5% YoY to ₹2,331.02 million.
Net Profit for the quarter dipped 3.7% YoY to ₹150.02 million due to higher operating costs.
9M FY26 Revenue reached ₹6,655.90 million, up from ₹5,571.73 million in the previous year.
Employee benefit expenses surged to ₹420.48 million in Q3 FY26 compared to ₹321.72 million in Q3 FY25.
Board approved the dissolution of Windlas Inc. USA, a non-operative wholly-owned subsidiary.
👀 What to Watch
While revenue growth is robust, the margin pressure from rising employee costs warrants caution; investors should hold for long-term CDMO prospects.
NDL Ventures Clarifies Q2 FY26 Filing Discrepancies; Reports Net Profit of ₹28.35 Lakh
NDL Ventures Limited has provided clarifications to the NSE regarding technical discrepancies in its Q2 FY26 financial filings, including machine-readability and segment reporting. The company reported a net profit of ₹28.35 lakh for the quarter ended September 30, 2025, up from ₹20.92 lakh in the corresponding quarter of the previous year. Total income for the quarter stood at ₹120.15 lakh, while the company maintains a single business segment in 'Other Financial Services'. A key ongoing development is the proposed merger with Hinduja Leyland Finance Limited, which has received a No Objection Certificate from the RBI.
Key Highlights
Net Profit for Q2 FY26 increased to ₹28.35 lakh compared to ₹20.92 lakh in Q2 FY25.
Total Income for the quarter was ₹120.15 lakh, a slight decrease from ₹124.23 lakh YoY.
Company confirmed it operates as a single segment entity under 'Other Financial Services'.
RBI has granted a No Objection Certificate (NOC) for the merger of Hinduja Leyland Finance Limited into the company.
Cash and bank balances as of September 30, 2025, stood at ₹506.67 lakh.
👀 What to Watch
Investors should focus on the progress of the Hinduja Leyland Finance merger as it is the primary catalyst for the company's future valuation. The current standalone financials are relatively small and the regulatory clarifications are procedural in nature.
Raymond Lifestyle Q3 FY26 Revenue Hits Record INR 1,883 Cr; EBITDA Up 23% YoY
Raymond Lifestyle reported its highest-ever quarterly revenue of INR 1,883 crores in Q3 FY26, driven by strong festive and wedding season demand. EBITDA grew 23% YoY to INR 271 crores, with margins expanding significantly to 14.4% from 12.3% in the previous year. The company maintains a robust balance sheet with net debt effectively at INR 15 crores and net cash of INR 155 crores. Management is successfully executing a premiumization strategy, evidenced by a INR 26 per meter increase in average selling prices.
Key Highlights
Record quarterly revenue of INR 1,883 crores with EBITDA margins expanding 210 bps to 14.4%
9M FY26 revenue grew 9% to INR 5,223 crores, while EBITDA rose 18% to INR 652 crores
Average selling price (ASP) increased by INR 26 per meter, reflecting successful product mix improvement
Strategic reduction in US market dependency from 50% to 35% to mitigate tariff uncertainties
Strong liquidity position with net cash of INR 155 crores and net debt of only INR 15 crores
👀 What to Watch
Investors should take note of the record revenue and margin expansion as evidence of strong brand equity and operational efficiency. The proactive diversification of the export portfolio and low debt levels make it a resilient play in the lifestyle segment.
IMP Powers Responds to SEBI; New Management Seeks Revocation of Trading Suspension
IMP Powers Limited has been acquired as a going concern by Electrify Energy Private Limited and Shri Rakesh Ramanlal Shah through an IBBI e-auction process. The new management has informed the exchange that they cannot provide clarifications on financial results for the quarter ended March 31, 2024, as those filings were managed by the Liquidator's office. Following an NCLT Ahmedabad order dated November 5, 2024, which granted specific reliefs, the company has requested the exchange to revoke the suspension of trading. The company is also seeking the listing of new shares to be allotted under the acquisition terms.
Key Highlights
Company acquired as a going concern under Regulation 32(e) of IBBI Regulations by Electrify Energy Private Limited.
NCLT Ahmedabad order dated November 5, 2024, granted reliefs and concessions to the successful auction purchasers.
New management unable to clarify March 2024 financial reporting as it was handled by the Liquidator.
Formal request for revocation of trading suspension and listing of new shares submitted on January 31, 2025.
👀 What to Watch
Investors should closely monitor the exchange's decision on the revocation of trading suspension and the specific terms of the new share allotment. The stock remains high-risk as it transitions from liquidation to new management control.
IMP Powers Clarifies Financial Reporting Status Following Liquidation and Ownership Change
IMP Powers Limited has responded to the Exchange's clarification request regarding financial results from May 2023. The company was acquired as a going concern by Electrify Energy Private Limited and Shri Rakesh Ramanlal Shah through an e-auction under IBBI Liquidation Regulations. The new management stated they cannot comment on past reporting as it was handled by the Liquidator's office. The company has already approached the exchange to revoke the trading suspension and list new shares following an NCLT order dated November 5, 2024.
Key Highlights
Company acquired as a going concern by Electrify Energy Private Limited and Shri Rakesh Ramanlal Shah
NCLT Ahmedabad order dated 05.11.2024 granted specific reliefs and concessions to the new owners
Management unable to clarify May 2023 financial results as data remains with the Liquidator's office
Formal request submitted to the Exchange on 31.01.2025 for revocation of trading suspension
New shares are pending allotment and listing as per the cited NCLT order
👀 What to Watch
Investors should monitor the Exchange's response regarding the revocation of the trading suspension and the listing of new shares. The stock remains a high-risk 'watch' as the company transitions from liquidation back to active operations.
IMP Powers Acquired as Going Concern; New Management Seeks Trading Revocation
IMP Powers Limited has been acquired as a going concern by Electrify Energy Private Limited and Shri Rakesh Ramanlal Shah through an e-auction under IBBI regulations. The Hon'ble NCLT Ahmedabad issued an order on November 5, 2024, granting specific reliefs and concessions to the successful auction purchasers. The current management is unable to clarify financial results from March 2023 as they were prepared by the Liquidator's office and records were not transferred. The company has formally requested the stock exchange to revoke the suspension of trading and list new shares to be allotted under the NCLT order.
Key Highlights
Company purchased as a going concern under Regulation 32(e) of IBBI Regulations by Electrify Energy consortium.
NCLT Ahmedabad order dated November 5, 2024, granted reliefs and concessions to the new management.
Formal request submitted to the exchange on January 31, 2025, for revocation of trading suspension.
New shares are scheduled to be allotted as per the court-approved acquisition plan.
👀 What to Watch
Investors should closely monitor the exchange's decision regarding the revocation of the trading suspension and the terms of the new share allotment. While the exit from liquidation is positive, the lack of access to historical financial data by new management adds a layer of uncertainty.
Raymond Lifestyle Q3FY26: EBITDA Grows 23% to ₹271 Cr; Domestic Demand Offsets Export Weakness
Raymond Lifestyle reported a 5% YoY increase in total income to ₹1,883 Cr for Q3FY26, driven by strong domestic performance in Branded Textiles which grew 11%. EBITDA saw a significant jump of 23% to ₹271 Cr, with margins expanding by 210 bps to 14.4% due to a better product mix and operating leverage. However, the Garmenting segment revenue fell 17% YoY to ₹258 Cr due to US tariff uncertainties and weak international order books. The company maintains a healthy balance sheet with net debt at just ₹15 Cr and a total retail footprint of 1,675 stores.
Key Highlights
Total Income grew 5% YoY to ₹1,883 Cr, while EBITDA rose 23% to ₹271 Cr in Q3FY26.
Branded Textile segment revenue increased 11% to ₹951 Cr with a robust 21.8% EBITDA margin.
Garmenting revenue declined 17% to ₹258 Cr due to global headwinds and US tariff uncertainty.
Retail network expanded to 1,675 stores with 21 new openings and 9 exits during the quarter.
Net Profit before exceptional items rose 54% to ₹100 Cr, though a ₹57 Cr labor code provision impacted final results.
👀 What to Watch
Investors should focus on the strong margin expansion in the domestic textile business and monitor the recovery in the garmenting export segment. The company remains a solid play on the Indian wedding and festive consumption cycle with a very lean balance sheet.
Raymond Lifestyle Appoints Prasad Ellatch Chathuar as CFO; 28 Years Experience
Raymond Lifestyle Limited has appointed Mr. Prasad Ellatch Chathuar as the Chief Financial Officer effective January 27, 2026. He succeeds Mr. Vishal Raigagla, who had been serving as the Interim CFO since October 29, 2025. Mr. Chathuar is a seasoned professional with 28 years of experience in the consumer industry, including a previous role as CFO at Bajaj Electricals Limited. This transition from an interim to a permanent, highly qualified CFO is expected to provide long-term stability to the company's financial leadership.
Key Highlights
Mr. Prasad Ellatch Chathuar appointed as CFO and Key Managerial Personnel effective January 27, 2026.
Brings 28 years of experience from Bajaj Electricals, Voltas (17 years), and Emami Paper Mills (5 years).
Replaces Interim CFO Vishal Raigagla, who held the position since October 29, 2025.
Educational qualifications include Chartered Accountant, Cost Accountant, and a Harvard University Executive Certification.
👀 What to Watch
The appointment of a permanent CFO with significant industry experience is a positive development for corporate governance. Investors should view this as a stabilizing move for the company's financial strategy and execution.
Raymond Lifestyle Appoints Prasad Ellatch Chathuar as CFO; Succeeds Interim CFO
Raymond Lifestyle Limited has appointed Mr. Prasad Ellatch Chathuar as its permanent Chief Financial Officer, effective January 27, 2026. He replaces Mr. Vishal Raigagla, who had been serving as the Interim CFO since October 29, 2025. Mr. Chathuar brings 28 years of extensive experience in the consumer industry, having previously served as the CFO of Bajaj Electricals Limited and holding senior roles at Voltas for 17 years. This transition from interim to permanent leadership marks a significant step in stabilizing the management of the newly listed entity.
Key Highlights
Mr. Prasad Ellatch Chathuar appointed as CFO and Key Managerial Personnel effective January 27, 2026.
The new CFO brings 28 years of experience, including a prior CFO role at Bajaj Electricals and 17 years at Voltas.
Mr. Vishal Raigagla ceases to be the Interim CFO after serving in the role since October 2025.
Mr. Chathuar is a Chartered Accountant and Cost Accountant with an Executive Certification in Finance from Harvard University.
👀 What to Watch
Investors should view the appointment of a highly experienced permanent CFO as a positive move for corporate governance and financial strategy. Monitor the company's upcoming financial disclosures for any shifts in capital allocation or business transformation strategies under the new leadership.
Raymond Lifestyle Q3 Revenue Up 9% to ₹1,466 Cr; Operating Margins Improve to 13.85%
Raymond Lifestyle reported a 9.4% YoY increase in standalone revenue to ₹1,466.23 crore for Q3 FY26. While operating margins improved significantly to 13.85% from 11.32% in the previous year, net profit for the quarter declined slightly to ₹49.45 crore due to a one-time exceptional loss of ₹42.68 crore. For the nine-month period ending December 2025, the company showed robust performance with net profit more than doubling to ₹112.94 crore. The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.11x.
Key Highlights
Revenue from operations grew 9.4% YoY to ₹1,46,623 lakhs in Q3 FY26.
Operating margin expanded to 13.85% in Q3 FY26 compared to 11.32% in Q3 FY25.
Net profit for the nine-month period (9M FY26) surged to ₹11,294 lakhs from ₹5,549 lakhs YoY.
Quarterly bottom line was impacted by an exceptional loss of ₹4,268 lakhs.
Interest Service Coverage Ratio remains healthy at 4.59 for the quarter.
👀 What to Watch
Investors should look past the quarterly net profit dip caused by exceptional items and focus on the strong operational margin expansion and 9-month growth trajectory. The stock remains a watch for continued efficiency in the lifestyle segment.
Raymond Lifestyle Q3 Revenue Grows 9.4% YoY to ₹1,466 Cr; Operating Margins Expand to 13.85%
Raymond Lifestyle Limited reported a steady 9.4% YoY increase in standalone revenue for Q3 FY26, reaching ₹1,466.23 crore. While Profit After Tax (PAT) for the quarter dipped 7.2% YoY to ₹49.45 crore due to an exceptional loss of ₹42.68 crore, the company's operational efficiency improved with operating margins rising to 13.85% from 11.32%. The nine-month performance remains exceptionally strong, with PAT more than doubling to ₹112.94 crore compared to ₹55.49 crore in the previous year. The company maintains a robust balance sheet with a low debt-to-equity ratio of 0.11.
Key Highlights
Standalone revenue from operations increased 9.4% YoY to ₹1,466.23 crore in Q3 FY26.
Operating margin improved significantly to 13.85% in Q3 FY26 from 11.32% in Q3 FY25.
Nine-month PAT (Apr-Dec 2025) surged 103% YoY to ₹112.94 crore.
Quarterly PAT was impacted by an exceptional loss of ₹42.68 crore, resulting in a 7.2% YoY decline to ₹49.45 crore.
Financial health remains strong with a Debt-Equity ratio of 0.11 and an Interest Service Coverage Ratio of 4.59x.
👀 What to Watch
Investors should look past the quarterly PAT dip caused by one-time exceptional items and focus on the significant margin expansion and strong 9-month growth trajectory. The stock remains a solid play in the lifestyle and branded apparel segment given its improving operational metrics.
